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Objective: The purpose of this report is to describe the clinical use of antithrombin
III concentrate in 53 patients who were found, in the operating room before car-
diopulmonary bypass, to be heparin resistant.
Method: Resistance to heparin was determined to be present when greater than 600
U/kg body weight of heparin failed to prolong the kaolin-activated clotting time to
more than 600 seconds in 53 aprotinin-treated patients. Blood samples were
obtained for subsequent antithrombin III activity determination. Patients were then
administered 500 U of antithrombin III concentrate, and the activated clotting time
was remeasured. If the activated clotting time remained less than 600 seconds, a
second 500-U dose was given.
Results: Of the 53 patients, 45 (85%) had subnormal measured antithrombin III
activity, and the mean plasma antithrombin III activity level for the entire group was
67% (normal 80%-120%). Administration of antithrombin III concentrate (500 U in
45 patients and 1000 U in 8 patients) resulted in prolongation of the mean activated
clotting time from 492 to 789 seconds without additional heparin. The mean heparin
dose response increased from 36.5 to 69.3 s·U–1·mL–1 with antithrombin III treat-
ment. Only one patient did not achieve the target activated clotting time, despite
administration of greater than 600 U/kg heparin and 1000 U of antithrombin III
concentrate, and was treated with fresh-frozen plasma.
Conclusions: On the basis of the criterion used in this report, most of the patients
defined as being heparin resistant had subnormal plasma antithrombin III activity.
Treatment with antithrombin III concentrate resulted in potentiation of the heparin
effect to meet predetermined activated clotting time thresholds and allow for car-
diopulmonary bypass.
Clot formation during cardiopulmonary bypass (CPB) is prevented bythe administration of heparin to catalyze the anticoagulant activity ofendogenous antithrombin III (AT). In the operating room heparin-induced anticoagulation is most often monitored by the activatedclotting time (ACT), and occasionally, patients undergoing heartsurgery are identified as heparin resistant when large heparin doses
fail to prolong the ACT to a level judged necessary for CPB.1 This resistance to
heparin, actually a state of an altered heparin dose response, is attributed to subnor-
mal plasma AT activity, and heparin-resistant patients are often administered fresh-
frozen plasma as a source of AT. Preparation of plasma, however, requires time for
ordering, thawing, and delivery to the operating room and has a risk of viral trans-
mission. Commercially prepared purified lyophilized human AT concentrates are
available and may be stored in the operating room for immediate use. Levy and asso-
ciates2 reported that AT concentrate potentiated heparin responsiveness when added
in vitro to blood drawn from patients with subnormal AT activity. Recently, Williams
and associates3 reported the administration of AT concentrate to 44 heparin-resistant
patients and found it to compare favorably with results in a group of 41 similar
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patients who were treated with additional heparin. This
report describes 53 patients who were found, at the time of
surgical intervention, to have a diminished response to
heparin and who were treated with AT concentrate. Before
AT concentrate administration, blood was drawn from each
patient for determination of AT activity.
Materials and Methods
The patients described in this report underwent operations during a
54-month period (November 1995 through May 2000). Fifty-three
patients were identified as heparin resistant in the operating room
before the institution of CPB on the basis of the failure of greater
than 600 U/kg heparin to prolong the kaolin ACT to longer than
600 seconds. All 53 patients received aprotinin (38 with high-dose
regimen and 15 with low-dose regimen) for various indications.4
Initial heparinization was performed with the loading dose of 450
U/kg porcine heparin. ACT determinations were made with tubes
containing the activator kaolin by using the Hemochron Model
#801 (Technidyne Corp, Edison, NJ), according to the manufac-
turer’s specifications. If the ACT was not sufficiently prolonged,
then a second dose of heparin was administered so that the total
dose of heparin exceeded 600 U/kg, and the ACT measurement was
then repeated. If the ACT remained at less than the target level,
blood was drawn from the patient for AT concentration determina-
tion. A single vial of AT concentrate (either Thrombate III, Bayer
Corporation, Elkhart, Ind, or ATnativ, Pharmacia, Stockholm,
Sweden) containing approximately 500 U of AT was administered
through a central venous catheter over 3 to 5 minutes, and the ACT
measurement was repeated. If the ACT was not sufficiently pro-
longed, a second vial of AT concentrate was administered.
Of the 53 patients, 24 (45%) were women; the average age was
71 years, and 21 (40%) were older than 75 years of age. Thirty-six
of the 53 operations were urgent, 7 were emergencies, and 10 were
elective. The following procedures were performed: coronary
artery bypass (n = 37), valve replacement with or without coronary
bypass (n = 14), and other (n = 2). The operation was a repeat ster-
notomy for 13 (25%) patients. Preoperative heparin exposure was
present in 41 (77%) patients: continuous infusion in 38, heparin
associated with dialysis in 2, and low-molecular-weight heparin in
1 patient. Eight (15%) patients had intra-aortic balloon pumps in
place before the operations.
All operations were conducted with CPB. The pump prime
solution contained 10,000 U of heparin. During bypass, the ACT
was measured at 30-minute intervals. For these aprotinin-treated
patients, a fixed-dose regimen was used, with heparin maintenance
doses (100 U/kg) administered every 60 minutes of CPB, irre-
spective of ACT duration.5 After separation from bypass, the ini-
tial protamine dose was 0.5 mg per 100 total heparin units.
The blood samples obtained for AT activity assay were drawn
into tubes containing 3.2% trisodium citrate, centrifuged for sepa-
ration of the plasma from the red cells and platelets, and then
frozen. Assay of the plasma for AT activity was performed with
colorimetric analysis (Stachrom; Diagnostica Stago, Parsippany,
NJ). Results of the assay are expressed as percentages (range of
normal activity, 80%-120%). Because the results of these determi-
nations were not available until 24 to 48 hours after collection,
they were not used to direct therapy.
Heparin dose-response relationships (HDRRs) were evaluated by
using generated heparin dose-response slope values to facilitate the
assessment of the potential effects of AT replacement on ACT
responsiveness to heparin. Estimates of circulating whole-blood
heparin concentration (WBHC) in units per milliliter were calculated
by dividing the total heparin dose (in units) by the patient’s blood
volume (in milliliters). Increases in clot times after heparin adminis-
tration (HDRR 1) or after AT concentrate administration (HDRR 2)
were calculated by using baseline, postheparin, and post-AT concen-
trate ACT values and the following formulas, respectively:
HDRR 1 = Postheparin ACT – Baseline ACT/WBHC;
HDRR 2 = Postheparin ACT – Baseline ACT/WBHC.
These HDRR values were then compared with each by using a
paired t test. The relationship between AT levels, WBHC values,
and HDRR values was then assessed with multivariate linear
regression statistical models.
Results
The mean per patient total heparin dose before AT concen-
trate administration was 49,745 U (642 U/kg), and the mean
postheparin ACT duration was 492 seconds. The mean total
heparin dose for the procedure was 71,032 U per patient,
and the mean CPB time was 125 minutes. The mean plasma
AT activity level of the 53 patients was 67%, and the
median value was also 67% (range, 33%-102%; SD, 15%).
Eight patients had serum AT levels greater than the lower
limit of normal (80%), whereas 5 had severely subnormal
levels (≤50%). The subgroup of patients with no preopera-
tive heparin exposure (n = 12) had a mean AT activity level
of 72% (range, 54%-102%).
Figure 1 shows each individual patient’s ACT durations
after the administration of greater than 600 U/kg heparin
Figure 1. Scattergraph showing the apparent lack of correlation
between kaolin ACT duration and AT activity after administration
of greater than 600 U/kg heparin in 53 patients (r = 0.01).
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and the measured AT activity before treatment with AT con-
centrate. There appeared to be no correlation between the
postheparin ACT and the magnitude of AT activity (r =
0.01). In the group of patients with ACT durations shorter
than 480 seconds (a commonly used ACT threshold), 84%
were AT deficient (16/19), which is nearly identical to the
proportion of AT-deficient patients (85%) in the group with
ACTs longer than 480 seconds (29/34, Table 1). After AT
concentrate infusion (500 U in 45 patients and 1000 U in 8
patients) with no additional heparin, the mean ACT level
rose from 492 to 789 seconds (Figure 2).
Eight patients required a second dose (approximately
500 U) of AT concentrate because of inadequate ACT pro-
longation after the first dose. The mean plasma AT level of
these 8 patients was 74% (range, 56%-86%). Adequate
ACT prolongation occurred in 7 of these patients after the
second dose, and one required fresh-frozen plasma. Eight
patients had normal AT activity determinations (mean,
92%; range, 82%-102%). Six of these patients achieved
ACT durations of longer than 600 seconds after the initial
500-U dose of AT concentrate, and one received 1000 U to
reach this ACT. One patient (whose pretreatment AT activ-
ity was 86%), despite treatment with 55,000 U of heparin
and 1000 U of AT concentrate, required 2 U of plasma to
raise the ACT from 470 to 673 seconds.
AT concentrate administration resulted in a greater
response in ACT values, as demonstrated by statistically
greater (P < .0001) HDRR values after AT concentrate (69.3
± 29 s·U–1·mL–1) when compared with the values before
administration of AT concentrate (36.5 ± 9.0 s·U–1·mL–1).
In addition, AT levels (P = .03) and heparin concentration
values (P = .03) were independently associated with ACT
response to heparin (ie, HDRR values) before administra-
tion of AT concentrate. When assessing the factors associ-
ated with AT levels, only HDRR values before
administration of AT concentrate were predictive (P = .03).
Discussion
Anticoagulation is maintained during CPB to prevent both
catastrophic thrombosis and subclinical thrombin forma-
tion, which may contribute to intraoperative clotting factor
consumption and postoperative coagulopathy. For satisfac-
tory anticoagulation, sufficient levels of both endogenous
AT and exogenously administered heparin are required. In
vitro studies by Despotis and associates6 suggest that the
administration of AT to heparin-resistant patients may help
to preserve the hemostatic system during CPB.
Acquired AT deficiency in patients undergoing cardiac
surgery is associated with preoperative heparin treatment
and intra-aortic balloon pump counterpulsation.1-3,6 In this
report 85% of the patients had been exposed to heparin
shortly before surgical intervention. In our practice 29% of
1047 patients undergoing coronary artery bypass grafting
surgery were treated with intravenous heparin just before
surgical intervention in 1999 compared with 22% of our
patients in 1989 and 1% in 1979. This reflects the increas-
ingly urgent nature of contemporary cardiac surgery prac-
tice and the determination that heparin is an effective
short-term therapy for acute coronary syndromes. As
greater numbers of patients require preoperative heparin
therapy and urgent surgical repair, it is expected that an
increasing proportion of AT-deficient patients will be pre-
senting for operations.
The patients in this report are a select group in that they
all received prophylactic aprotinin, were found to be
heparin resistant, had AT activity measurements, and were
treated with AT concentrate. The aprotinin was adminis-
tered before the withdrawal of blood for AT activity deter-
mination. Aprotinin administration does not, however,
reduce plasma AT activity and is actually associated with
increased AT activity during CPB.7 Patients in this report
were considered to be heparin resistant if the ACT remained
Figure 2. In 53 heparin-resistant patients the administration of AT
concentrate (500 U in 45 patients and 1000 U in 8 patients) caused
prolongation of the mean kaolin ACT from 492 to 798 seconds. This
was associated with an increase in the slope of the HDRR value
from 36.5 to 69.3 s·U–1·mL–1.
TABLE 1. AT activity and ACT duration after treatment with
600 U/kg heparin or greater (mean dose, 642 U/kg)
ACT <480 s ACT 480-599 s
AT activity <80% 16/19 (84%) 29/34 (85%)
AT activity >80% 3/19 (16%) 5/34 (15%)
The incidence of subnormal AT activity (<80%) was nearly identical in the
group of patients with an ACT of less than 480 seconds and the group of
patients with an ACT of 480 to 599 seconds.
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shorter than 600 seconds after the administration of 600
U/kg heparin. This ACT threshold is modestly (25%) longer
than the kaolin ACT threshold (480 seconds) that is sug-
gested as a minimum by aprotinin’s manufacturer.8 This
heparin protocol is based on the observation that larger
heparin doses reduce thrombin formation and clotting fac-
tor consumption during CPB more effectively than lower
doses,6,9 and when used with aprotinin, bleeding is
reduced.10 Although aprotinin does not affect the kaolin
ACT to the extent to which it affects the celite ACT, at high
aprotinin concentrations (400 KIU/mL), the kaolin ACT is,
in fact, prolonged somewhat.11 Furthermore, it has been
demonstrated that the kaolin ACT response to heparin
demonstrates a great deal of interpatient variability and that
ACT values do not correlate well with plasma heparin activ-
ity during CPB.12
Various criteria have been used to define the state of
heparin resistance. In 1994, Staples and colleagues1 defined
heparin resistance as a failure of 500 U/kg heparin to pro-
long the ACT (activator not specified) to 480 seconds. In
1995, Irani13 reported the criterion of an ACT of 400 sec-
onds after 300 U/kg heparin. More recently, Williams and
associates3 defined heparin resistance to be present when
450 U/kg heparin failed to prolong the celite-activated ACT
to longer than 480 seconds in nonaprotinin-treated patients
and longer than 600 seconds in aprotinin-treated patients. In
effect, the definition used in the author’s practice is quite
similar to those reported by Staples and colleagues1 and by
Williams and coworkers.3 Although the target ACT (600
seconds) is 25% longer than that required by Staples and
colleagues or Williams and coworkers, the amount of
heparin administered (600 U/kg) to achieve this goal ACT
is also greater (20% more than Staples and colleagues and
33% more than Williams and coworkers). The definition of
heparin resistance used in this series of patients success-
fully identified a group of patients with a high proportion
(45/52 [85%]) of AT deficiency. In a similar fashion,
Williams and colleagues3 found 77% of their heparin-resis-
tant patients to actually have subnormal AT activity. As
shown in Table 1, 34 patients in this report had ACT dura-
tions of between 480 and 599 seconds after receiving more
than 600 U/kg heparin. Of these, 29 (85%) had subnormal
AT activity (mean AT activity for this group, 66%). Thus the
heparin definition used in this report effectively identified
patients for whom AT supplementation (either by plasma or
AT concentrate administration) was likely indicated.
AT concentrate is a pooled human plasma product that
has been subjected to fractionation procedures and heating
to 60°C for not less than 10 hours to cause viral inactiva-
tion.14 One vial (containing approximately 500 U of AT) is
roughly equivalent to the transfusion of 2 U of fresh-frozen
plasma, which has approximately 1 U of AT per milliliter.
More specifically, AT activity is increased by approximately
1.4% for each unit of AT concentrate per kilogram of body
weight.15 The drug can be stored (refrigerated) in the oper-
ating room and be readily available for reconstitution and
administration, thus eliminating the delay associated with
ordering, thawing, and delivering fresh-frozen plasma from
the blood bank. Williams and colleagues3 compared AT
concentrate to the administration of more heparin in
patients who did not achieve predetermined celite ACT
durations (see above) after initial treatment with 450 U/kg
heparin. In that study AT concentrate (1000 U) was found to
be more effective and faster for obtaining adequate antico-
agulation than treatment with additional heparin. Likewise,
in all but one of the 53 heparin-resistant patients of this
report, AT concentrate treatment (either 500 or 1000 U)
effectively prolonged the ACT, allowing for the institution
of CPB without additional heparin or fresh-frozen plasma.
This was associated with the near doubling of the heparin-
ACT dose-response slope values that were observed after
the administration of AT concentrate.
In this series of patients determined to be heparin resis-
tant by means of ACT criteria, the majority had subnormal
plasma AT activity, and the administration of AT concentrate
increased the mean ACT by nearly 300 seconds. Although
these findings demonstrate potentiation of heparin’s effect,
they do not lead to a claim of improved outcomes with AT
concentrate administration compared with fresh-frozen
plasma or compared with no treatment at all for patients who
are found, intraoperatively, to be resistant to heparin. Nor do
they prove the necessity for AT repletion, even for docu-
mented AT-deficient patients. It is known, however, that AT
activity declines from baseline by about 50% during CPB,
and thus very low levels would be expected to develop in
patients with prebypass AT deficiency.16
The following may be concluded from this experience.
First, failure of greater than 600 U/kg heparin to raise the
kaolin-activated ACT to more than 600 seconds is associ-
ated with subnormal AT activity in the majority of patients.
Thus heparin-resistant patients, on the basis of this defini-
tion, are very often AT deficient, although there did not
appear to be a correlation between postheparin ACT dura-
tion and measured AT activity. Second, treatment of
heparin-resistant patients with AT concentrate resulted in a
significant increase in the ACT response to heparin with
prolongation of the ACT to permit the institution of CPB.
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